Olaparib and niraparib as maintenance therapy in patients with newly diagnosed and platinum-sensitive recurrent ovarian cancer: A single-center study in China

CONCLUSIONS: Olaparib and niraparib were effective in patients with ovarian cancer without any new safety signals except for skin pigmentation. In patients with BRCAm, the 24-month PFS of the PARPi used in the PSR-M setting was even higher than that used in the FL-M setting.PMID:38679485 | DOI:10.1097/CM9.0000000000003125

Source: Chinese Medical Journal - April 28, 2024 Category: General Medicine Authors: Dengfeng Wang Xunwei Shi Jiao Pei Can Zhang Liping Peng Jie Zhang Jing Zheng Chunrong Peng Xiaoqiao Huang Xiaoshi Liu Hong Liu Guonan Zhang Source Type: research